Anlotinib may have a therapeutic effect on papillary craniopharyngiomas without the BRAFv600e mutation

Anlotinib may have a therapeutic effect on papillary craniopharyngiomas without the BRAFv600e mutation

Abstract Background Although successful treatment of papillary craniopharyngiomas (PCPs) with BRAFv600e inhibitors has been reported in clinical trials, studies have shown that approximately 10% of PCPs lack the BRAFv600e mutation and that BRAFv600e inhibitors may not be significantly effective agai...

Full description

Bibliographic Details
Main Authors: Yilamujiang Ainiwan, Haomin Li, Yongjia Zheng, Songtao Wei, Junxiang Peng, Jing Nie, Chaofu Mao, Kunxiang Chen, Siyuan Chen, Ningyuan Liu, Can Li, Yan Chen, Shanqiang Qu, Yunji Wang, Mingfeng Zhou, Jian Mao, Fen Mei, Jingting Chen, Qiancheng Song, Songtao Qi, Jun Pan
Format: Article
Language:English
Published: BMC 2025-03-01
Series:Acta Neuropathologica Communications
Subjects:
Papillary craniopharyngioma
BRAFv600e mutation
Calcification
Vemurafenib
Anlotinib
Online Access:https://doi.org/10.1186/s40478-025-01972-7

Internet

https://doi.org/10.1186/s40478-025-01972-7

Similar Items